CoChat
Sign Up
Cited by 19Photodynamic Therapy Research StudiesNonmelanoma Skin Cancer StudiesNanoplatforms for cancer theranostics

Topical ALA–PDT modifies neutrophils’ chemiluminescence, lymphocytes’ interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies

Adamek, Mariusz, Kawczyk-Krupka, Aleksandra, Mostowy, Aleksandra, Czuba, Zenon, Krol, Wojciech, Kasperczyk, Slawomir, Jakobisiak, Marek, Golab, Jakub +1 more·2005·Photodiagnosis and Photodynamic Therapy
DOI 10.1016/s1572-1000(05)00004-9
Open this paper in CoChat — free account

Abstract

Background Photodynamic therapy (PDT) has been recognized as a noninvasive therapeutic approach for the effective treatment of tumors. It has been shown in studies conducted on malignant cell lines and various animal tumor models, that the interaction of photosensitizing substances with light leads to the release of cytotoxic substances and stimulates the immune response. Purpose The aim of our study was to analyze the immune system response in patients undergoing photodynamic therapy due to basal cell carcinoma (BCC). Methods Patients with skin malignancies have been treated by 10% delta-aminolevulinic acid (ALA) (Medac GmbH, Wedel, Germany) topically and light from a diode laser. Blood samples were obtained from each patient twice in the same day: before and 4h after photodynamic treatment procedure. In patients' serum the concentration of transforming growth factor beta1 (TGF-β1) was determined. Additionally the study has been conducted on lymphocytes and granulocytes from peripheral blood. In cell culture supernatants the concentration of interleukin 1beta (IL-1β), interleukin 2 (IL-2), interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα), the percentile composition of patients' lymphocytes and the chemiluminescence of neutrophils have been measured. Results We have observed a significant increase (p=0.015) in the intensity of the neutrophil chemiluminescence and significant diminution (p=0.006) of IL-1β concentration in supernatants. Similarly the serum level of TGF-β1 has been significantly decreased (p<0.001). Conclusion It is very likely that human immune system activity is modified by topical ALA-PDT and may potentially contribute to its final outcome.

Integrity signals

Registry

Crossref · 10.1016/s1572-1000(05)00004-9

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALA-PDT not only directly kills tumor cells but also elicits potent immune responses with important implications in the long-term therapeutic outcome.

    “ALA-PDT not only directly kills tumor cells but also elicits potent immune responses with important implications in the long-term therapeutic outcome.”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [150]

  • ALA-PDT induces the release of inflammatory cytokines such as TNFα, which promotes the infiltration of polymorphonuclear cells particularly neutrophils that can kill tumor cells directly by ROS release and indirectly by the subsequent antitumor immunity.

    “It induces the release of inflammatory cytokines such as TNFα, which promotes the infiltration of polymorphonuclear cells particularly neutrophils that can kill tumor cells directly by ROS release and indirectly by the subsequent antitumor immunity [149,150,151].”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [150]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Adamek, M., Kawczyk-Krupka, A., Mostowy, A., Czuba, Z., Krol, W., Kasperczyk, S., Jakobisiak, M., Golab, J., & Sieron, A.
Affiliations
Medical University of Silesia (PL)
Corresponding author
Adamek, Mariusz
ORCID
Venue
Photodiagnosis and Photodynamic Therapy
Publisher
Elsevier BV
Published
2005-03
Volume
2
Issue
1
Pages
65-72
ISSN
1572-1000 (ISSN-L)
DOI
10.1016/s1572-1000(05)00004-9
OpenAlex
W2082560775
Cited by
19
References
40
Citations by year
2025: 4 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 3 · 2018: 1 · 2015: 2
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Photodiagnosis and Photodynamic Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
photodynamic therapy, non-melanoma skin cancer, basal cell carcinoma, neutrophil chemiluminescence, IL-1β, TGF-β1, immune response, diode laser

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review